Biogen, desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment Aduhelm, has a shopping list of potential acquisitions, STAT has learned. And the company’s risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive.
The company, whose stock price is down nearly 50% since Aduhelm’s June approval, is working with Goldman Sachs to find potential buyout targets, according to a person familiar with the companies’ relationships who would share internal discussions only on the condition of anonymity.
Goldman provided Biogen with a list of smaller biotech companies that might fit with the company’s focus on neuroscience, the person said. The list includes Biohaven Pharmaceuticals, maker of commercially successful treatments for migraine; Aurinia Pharmaceuticals, which recently won approval for a drug to treat lupus; and Amylyx Pharmaceuticals, a firm seeking approval for an ALS treatment.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect